Physician profile
Andrew Evin Davidson
NPI 1134121718
$13,572.00
in general payments reported to CMS, 2019-2025
40 companies · $3,246 in 2025
The $3,246 reported for 2025 was more than what 78% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,369 · 2020: $1,290 · 2021: $1,791 · 2022: $1,602 · 2023: $2,179 · 2024: $2,095 · 2025: $3,246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,222 · Education: $274 · Consulting Fee: $23.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,221.92 |
| Education | $273.91 |
| Consulting Fee | $23.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,005.60 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Genzyme Corporation | $1,657.42 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,192.36 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $819.30 | 2020-2025 | Cuvitru, Takhzyro, Glassia |
| Csl Behring | $800.57 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Genentech USA, INC. | $698.33 | 2019-2025 | Xolair |
| Pfizer INC. | $574.81 | 2019-2025 | |
| Amgen INC. | $524.46 | 2021-2025 | Tezspire |
| Pharming Healthcare, INC. | $521.65 | 2019-2025 | Joenja, Ruconest |
| Biocryst US Sales Co., LLC | $483.04 | 2021-2025 | Orladeyo |
| Regeneron Healthcare Solutions, INC. | $451.61 | 2019-2025 | Dupixent |
| Alk-Abello, INC | $378.37 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $348.42 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $277.73 | 2020-2025 | |
| Teva Pharmaceuticals USA, INC. | $239.45 | 2019-2022 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Davidson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.